在患有低风险血清度的患者中,乙氨基毒性的模式
Abdullah M Alhammad1, Ghada Alajmi2, Aljawharah Alkhodair2
1Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
The Journal of international medical research
|July 28, 2024
概括
过量服用后乙氨基水平低 (<150微克/毫升) 的患者肝损伤风险最小. 这包括具有额外风险因素的个体,表明对乙氨基毒性的安全门.
科学领域:
- 毒理学 毒理学 毒理学
- 肝病学 肝病学是一种肝病学.
- 紧急医疗 紧急医疗
背景情况:
- 英国在2012年将乙氨基毒性治疗值降至100μg/ml,摄入后4小时.
- 乙氨基 (偏醇) 过量剂量管理依赖于血清度名组图.
- 在较低的血清度下评估毒性对于改进治疗指南至关重要.
研究的目的:
- 在过量服用后血清乙氨基度低 (<150微克/毫升) 的患者中评估生化标志物和肝毒性.
- 为了确定表现为亚美诺芬水平低于修订后的治疗值的患者的肝毒性风险.
主要方法:
- 对103名急性乙氨基过量服用的患者进行了回顾性队列研究.
- 纳入标准:血清乙氨基<150μg/ml和已知的摄入时间.
- 排除标准:血清乙氨基>150微克/毫升或摄入时间不明.
主要成果:
- 中位摄入的乙氨基剂量为5000毫克,基线血清度的中位数为42μg/ml.
- 没有患者出现肝毒性,即使是那些多次摄入产品或其他危险因素的患者.
- 20名患者接受了乙囊治疗,没有任何不良反应.
结论:
- 急性乙氨基过量和血清度低于150微克/毫升的患者肝毒性风险较低.
- 这一发现支持英国目前的治疗门,并表明更大的安全空间.
- 在这个队列中没有观察到明显的肝损伤,无论附加的危险因素.
相关概念视频
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
110
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
110
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
174
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
174
Nonlinear Pharmacokinetics: Causes of Nonlinearity
165
Nonlinearity in drug pharmacokinetics is caused by various factors influencing how a drug is absorbed, distributed, metabolized, and excreted. Understanding these nonlinear processes is crucial for predicting drug behavior in the body and optimizing drug dosing regimens.
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
165
Nonlinear Pharmacokinetics: Overview
331
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinearity can arise due to the saturation of plasma protein-binding or...
331
Time Course of Drug Effect
2.0K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.0K
Drug Distribution: Tissue Binding
2.6K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
2.6K


